By Fineline Cube 
Chia Tai Tianqing Pharmaceutical Group, a wholly owned subsidiary of Sino Biopharmaceutical Ltd (HKG: 1177), and Shanghai Reunion Biotechnology Co., Ltd. have formed a strategic alliance to accelerate the commercialization of Respacio™, an absorbable isolation hydrogel designed to protect healthy tissues during cervical cancer radiotherapy.
The partnership focuses on resource integration and complementary strengths: Reunion brings the innovative medical device, while Chia Tai Tianqing contributes its established commercial infrastructure, including hospital access, sales force coverage, and distribution logistics across mainland China.
Product & Clinical Value Proposition
| Feature | Detail |
|---|---|
| Product | Respacio™ – absorbable, biocompatible hydrogel spacer |
| Indication | Radioprotection in cervical cancer radiotherapy |
| Mechanism | Temporarily creates physical separation between tumor and adjacent organs (e.g., rectum, bladder) to reduce radiation exposure |
| Absorption Profile | Fully resorbed within weeks post-treatment, eliminating need for removal |
| Clinical Benefit | Reduces incidence of radiation-induced toxicities (e.g., proctitis, cystitis), improving quality of life and enabling optimal dosing |
Strategic Collaboration Framework
| Area | Execution Plan |
|---|---|
| Market Expansion | Leverage Chia Tai Tianqing’s presence in >3,000 Tier II/III hospitals nationwide |
| End-User Coverage | Joint training for radiation oncologists and medical physicists on hydrogel placement protocols |
| Patient Access | Streamline procurement through hospital tender processes and provincial medical insurance negotiations |
| Commercial Transition | Rapid scale-up from regulatory approval to routine clinical adoption via integrated launch plan |
Market Context & Unmet Need
- Cervical Cancer Burden: China accounts for ~110,000 new cases annually—nearly 20% of global incidence
- Radiotherapy Standard: Critical component of treatment, yet >60% of patients experience Grade ≥2 gastrointestinal or genitourinary toxicity
- Innovation Gap: Respacio is among the first locally developed hydrogel spacers tailored for pelvic anatomy in Asian populations
Strategic Implications
For Sino Biopharmaceutical, the deal diversifies its oncology portfolio beyond drugs into adjunctive medical technologies, aligning with its “comprehensive cancer care” strategy. For Reunion Biotech, the partnership provides immediate scale without building costly commercial operations—a model increasingly adopted by Chinese medtech innovators.
Forward‑Looking Statements
This brief describes a commercial collaboration. Revenue impact, market penetration, and reimbursement status remain subject to execution and healthcare policy developments.-Fineline Info & Tech